<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04441931</url>
  </required_header>
  <id_info>
    <org_study_id>18029</org_study_id>
    <secondary_id>J2Z-MC-PGAA</secondary_id>
    <nct_id>NCT04441931</nct_id>
  </id_info>
  <brief_title>A Study of LY3832479 (LY-CoV016) in Healthy Participants</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Immunogenicity of LY3832479 Given as a Single Intravenous Dose in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about the safety of LY3832479 and any side&#xD;
      effects that might be associated with it. Blood tests will be done to measure how much&#xD;
      LY3832479 is in the bloodstream and how long it takes the body to eliminate it. Participation&#xD;
      could last up to 16 weeks and may include up to 10 visits to the study center.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2020</start_date>
  <completion_date type="Actual">October 2, 2020</completion_date>
  <primary_completion_date type="Actual">October 2, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</measure>
    <time_frame>Baseline through Follow-up (Week 12)</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3832479</measure>
    <time_frame>Day 1: Pre-dose through Day 85</time_frame>
    <description>PK: AUC of LY3832479</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of LY3832479</measure>
    <time_frame>Day 1: Pre-dose through Day 85</time_frame>
    <description>PK: Cmax of LY3832479</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3832479</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3832479 administered intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3832479</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>LY3832479</arm_group_label>
    <other_name>LY-CoV016</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy as determined by medical evaluation including medical history and&#xD;
             physical examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)&#xD;
&#xD;
          -  Pregnant women and women of childbearing potential&#xD;
&#xD;
          -  Have a history or presence of cardiovascular (including hypertension), respiratory,&#xD;
             hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders&#xD;
             that, in the opinion of the investigator, are capable of significantly altering the&#xD;
             absorption, metabolism, or elimination of drugs, or of constituting a risk while&#xD;
             taking the investigational product, or of interfering with the interpretation of data&#xD;
&#xD;
          -  Have participated in a clinical study involving an investigational product, with last&#xD;
             dose within the past 30 days or 5 half-lives (whichever is longer) prior to dosing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 19, 2020</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 1, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

